N-hydroxy-N′-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1261-1266

  Saiko, Philipp ^a   Ozsvar Kozma, Maria ^a   Bernhaus, Astrid ^a   Jaschke, Margit ^a   Graser, Geraldine ^a   Lackner, Andreas ^a   Grusch, Michael ^a   Horvath, Zsuzsanna ^a   Madlener, Sibylle ^a   Krupitza, Georg ^a   Handler, Norbert ^b   Erker, Thomas ^b   Jaeger, Walter ^b   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arabino furanosylcytosine; HL 60 human promyelocytic leukemia cells; N hydroxy N (3,4,5 trimethoxyphenyl) 3,4,5 trimethoxybenzamidine; Resveratrol; Ribonucleotide reductase; Synergistic combination effects

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; CYTIDINE; ENZYME INHIBITOR; N HYDROXY N' (3,4,5 TRIMETHOXYPHENYL) 3,4,5 TRIMETHOXY BENZAMIDINE; N-HYDROXY-N'-(3,4,5-TRIMETHOXYPHENYL)-3,4,5-TRIMETHOXY-BENZAMIDINE; RESVERATROL; RIBONUCLEOTIDE REDUCTASE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYTARABINE; CYTIDINE; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; RIBONUCLEOTIDE REDUCTASES; STILBENES;

EID: 38449115124     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B and Fernandez-Salguero PM: The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 64: 1375-1386, 2002.
2. Zhou HB, Yan Y, Sun YN and Zhu JR: Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol 9: 408-411, 2003.
3. Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Vercauteren J, Belloc F, Billiard C, Dupouy M, Thiolat D, Kolb JP, Marit G, Reiffers J and Mossalayi MD: Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 23: 1327-1333, 2002.
4. Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA and Pandol SJ: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 98: 761-769, 2002.
5. Clement MV, Hirpara JL, Chawdhury SH and Perviaz S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD 95 signaling-dependent apoptosis in human tumor cells. Blood 92: 996-1002, 1998.
6. Dorrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731-4739, 2001.
7. Fontecave M, Lepoivre M, Elleingand E, Gerez C and Guittet O: Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421: 277-279, 1998.
8. Elford HL, Freese M, Passamani E and Morris HP: Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245: 5228-5233, 1970.
9. Gandhi V, Estey E and Plunkett W: Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol 370: 119-124, 1994.
10. Gandhi V and Plunkett W: Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50: 3675-3680, 1990.
11. Gandhi V, Kemena A, Keating MJ and Plunkett W: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52: 897-903, 1992.
12. Gandhi V, Estey E, Keating MJ and Plunkett W: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11: 116-124, 1993. (Pubitemid 23059984)
13. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM and Wilson MP: A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112: 127-137, 2001.
14. Nandy P, Lien EJ and Avramis VI: Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis. Anticancer Res 19: 1625-1633, 1999.
15. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E and Vannini V: Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276: 22586-22594, 2001.
16. Hsieh TC, Juan G, Darzynkiewicz Z and Wu JM: Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59: 2596-2601, 1999.
17. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M and Aggarwal BB: Resveratrol blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102: 987-995, 2003.
18. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P and Zappia V: Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250: 53-58, 1998.
19. Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, Greil R, Kofler R and Csordas A: Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 7: 834-842, 2000.
20. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T and Delaisse JM: Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 65: 9943-9952, 2005.
21. Kimura Y, Okuda H and Arichi S: Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834: 275-278, 1985. (Pubitemid 15072791)
22. Chung MI, Teng CM, Cheng KL, Ko FN and Lin CN: An antiplatelet principle of Veratrum formosanum. Planta Med 58: 274-276, 1992.
23. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G and Goldberg DM: The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-219, 1995.
24. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S and Tolomeo M: Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 46: 3546-3554, 2003.
25. Gosslau A, Chen M, Ho CT and Chen KY: A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts. Br J Cancer 92: 513-521, 2005.
26. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, and Gescher AJ: Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115: 194-201, 2005.
27. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay JF, Brouillard R and Raul F: Resveratrol analog (Z)-3,5,4′- trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107: 189-196, 2003.
28. Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, Erker T, Jaeger W, Fritzer-Szekeres M and Szekeres T: Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol 33: 329-335, 2005.
29. Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram HN, Klepal W, Szekeres T, Knasmuller S and Krupitza G: Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 9: 169-178, 2002.
30. Garrett C and Santi DV: A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99: 268-273, 1979.
31. Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van't Riet B, Jayaram HN and Elford HL: Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 34: 63-66, 1994.
32. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
33. Robinson BW, Im MM, Ljungman M, Praz F and Shewach DS: Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63: 6935-6941, 2003.